A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial

  • sponsor
    Factor Therapeutics
Updated on 23 November 2020


A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial


This study is a multi-center, randomized, double blind, placebo-controlled dose-response study designed to evaluate VF-001-DP as an adjunct to SC, versus Placebo and SC in the treatment of chronic VLUs. The SC therapy for VLUs is a moisture retentive ulcer dressing and multi-layer compression therapy. Mepitel® and Coban2® have been chosen to be used as SC in this study.

The study will have three (3) phases: Screening (2 weeks), Treatment Phase (13 weeks, with treatment up to 12 weeks) and Follow-Up (12 weeks).

Only patients whose study ulcer does not exhibit more than 30% change (increase or decrease) in ulcer size post-debridement between Screening Phase Visit (S1) and Treatment Phase Visit (T1) and who continue to meet eligibility criteria at T1 will be randomized to receive either the Active Treatment (VF001-DP low or high dose plus SC) or the Control Treatment (Placebo plus SC) in a ratio of 1:1:1.

For more information see: https://clinicaltrials.gov/ct2/show/NCT02973893?term=vf00102&rank=1

Contact: Anthony Bishop, a.bishop@factor-therapeutics.com for further information.

Condition Venous Leg Ulcers, Skin Wounds, Leg Ulcer
Clinical Study IdentifierTX146476
SponsorFactor Therapeutics
Last Modified on23 November 2020


Yes No Not Sure

Inclusion Criteria

At least 18 years old
Ankle-Brachial Pressure Index (ABI) =0.80. (Calculations will be made using measurements from both posterior tibial and dorsalis pedis arteries as well as both arms)
Presence of VLUs extending through the full thickness of the skin but not down to muscle, tendon or bone. In the case of more than one ulcer, the largest ulcer (compliant with study criteria) will be chosen as the study ulcer and treated in the study. Other ulcerations, if present on the same leg must be at least 2 cm apart from the study ulcer
Venous disease confirmed by Doppler ultrasonography to demonstrate reflux of >0.5 seconds in saphenous (great or small), calf perforators or the deep venous system. Patients with prior venous surgery (i.e., varicose vein stripping, endovenous ablation) may be included if they still demonstrate significant reflux in a remaining venous segment and the ulcer continues to suffer poor healing because of venous hypertension
Ulcer which has been present and treated with standard care (moisture retentive ulcer dressings and compression bandaging not limited to Mepitel® and Coban2®) for at least one month prior to the initial Screening Visit
Moderate severity ulcer at the T1 visit (post-debridement) complying with the following requirements of the Margolis Predictive Score Baseline Wound Area and Wound Duration
(a) 2.5 cm2 to not-more-than 5 cm2 and not-less-than 6 months or
(b) Not-less-than 5 cm2 to not-more-than 15 cm2 and not-more-than 6 months
Ulcer with a clean, granulating base free of adherent slough at the T1 visit (post-debridement)
Female patients of childbearing potential, willing to use acceptable methods of contraception (birth control pills, barriers, or sexual abstinence). A urine pregnancy test must be performed, and negative at the T1 visit
Patient able to understand the study procedures and willing to participate in the clinical study and able to comply with study visit schedule
Provide signed informed consent

Exclusion Criteria

Ulcer(s) deemed by the Investigator to be caused by a medical condition other than venous insufficiency. These may include, but are not limited to: fungal ulcerations, malignant ulcerations, diabetic (neuropathic) ulcerations, and ulcerations due to arterial insufficiency
Increase or decrease by >30% in the study ulcer surface area at the T1 visit post-debridement as compared to the S1 visit study ulcer surface area post-debridement
Ulcer exhibits clinical signs and symptoms of infection at S1to T1 in which case infection should be treated and the patient may after treatment be re-assessed for eligibility to enter into the study
Known allergy to any of the protocol-stipulated treatment procedures, or non-tolerance of multi-layer compression therapy
Ulcer which has undergone continuing high level of compression therapy for =12 months
Ulcer, which in the opinion of the Investigator is suspicious for cancer
A history of more than 2 weeks' treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to initial screening, or treatments with such medications during the screening period, or anticipated requirement of such medications during the course of the study
IGF-1 treatment or treatment with a product containing IGF-1
Treatment with Pentoxifylline (Trental®) within 30-days of S1 visit
Treatment with any investigational drug(s) or therapeutic device(s) within 30 days preceding screening (i.e., S1); or anticipated (patient or physician anticipates) use of any of these therapies during the course of the study
Malignant disease not in remission for 5 years or more, other than basal cell carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ, that have been successfully treated without evidence of recurrence or metastases
History of radiation at the ulcer site
As determined by medical history, presence of one or more medical conditions including renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the patient an inappropriate candidate for this ulcer healing study
Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history of known infection with Human Immunodeficiency Virus (HIV)
Previous participation in any VF001-DP study within the past 6 months
Ulcer has been previously treated with tissue engineered materials (e.g., Apligraf® or Dermagraft®) or other scaffold materials (e.g., Oasis®, Matristem®) within the last 30 days prior to S1
Ulcer which in the opinion of the Investigator might require negative pressure ulcer therapy or hyperbaric oxygen during the course of the study
New York Heart Association Class III and IV congestive heart failure, as defined by the following criteria
Class III: Symptoms with moderate exertion
Class IV: Symptoms at rest
Uncontrolled diabetes mellitus, defined as Hemoglobin A1C >10% confirmed by the Investigator
Ulcer on the dorsum of the foot or with more than 50% of the ulcer below the malleolus is excluded
Known history of acromegaly
Any other medical or psychological condition (including relevant laboratory abnormalities at screening) that, in the opinion of the Investigator, may suggest a new and/or insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his/her participation in this clinical trial, may make patient's participation unreliable, or may interfere with study assessments. The specific justification for patients excluded under this criterion will be noted in study documents (chart notes, CRFs, etc)
Women unwilling to use adequate birth control, if of reproductive potential and sexually active. Adequate birth control is defined as agreement to consistently practice an effective and accepted method of contraception throughout the duration of the study
Pregnancy or breast-feeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note